Tiong Kiam Ong

Tiong Kiam Ong

Auto-generated profile, based on publicly available information

Tiong Kiam Ong

Sarawak Heart Centre, Sarawak, Malaysia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
JAJung-Min Ahn
Jung-Min Ahn
DKDo-Yoon Kang
Do-Yoon Kang
SYSung-Cheol Yun
Sung-Cheol Yun
SHSeung Ho Hur
Seung Ho Hur
HPHun-Jun Park
Hun-Jun Park
FIfor the BEST Extended Follow-Up Study Investigators
for the BEST Extended Follow-Up Study Investigators
Background: Long-term comparative outcomes after percutaneous coronary intervention (PCI) with everolimus-eluting stents and coronary artery bypass grafting (CABG) are limited in patients with multivessel coronary artery disease. Methods: This prospective, multicenter, randomized controlled trial was conducted in 27 international heart centers and was designed to randomly assign 1776 patients with angiographic multivessel coronary artery disease to receive PCI with everolimus-eluting stents or CABG. After inclusion of 880 patients (438 in the PCI group and 442 in the CABG group) between July 2008 and September 2013, the study was terminated early because of slow enrollment. The primary end point was the composite of death from any cause, myocardial infarction, or target vessel revascularization. Results: During a median follow-up of 11.8 years (interquartile range, 10.6–12.5 years; maximum, 13.7 years), the primary end point occurred in 151 patients (34.5%) in the PCI group and 134 patients (30.3%) in the CABG group (hazard ratio [HR], 1.18 [95% CI, 0.88–1.56]; P=0.26). No significant differences were seen in the occurrence of a safety composite of death, myocardial infarction, or stroke between groups (28.8% and 27.1%; HR, 1.07 [95% CI, 0.75–1.53]; P=0.70), as well as the occurrence of death from any cause (20.5% and 19.9%; HR, 1.04 [95% CI, 0.65–1.67]; P=0.86). However, spontaneous myocardial infarction (7.1% and 3.8%; HR, 1.86 [95% CI, 1.06–3.27]; P=0.031) and any repeat revascularization (22.6% and 12.7%; HR, 1.92 [95% CI, 1.58–2.32]; P<0.001) were more frequent after PCI than after CABG. Conclusions: In patients with multivessel coronary artery disease, there were no significant differences between PCI and CABG in the incidence of major adverse cardiac events, the safety composite end point, and all-cause mortality during the extended follow-up. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT05125367 and NCT00997828.

1 January 2021 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
TYTeerapat Yingchoncharoen
Teerapat Yingchoncharoen
TWTao-Cheng Wu
Tao-Cheng Wu
DCDong-Ju Choi
Dong-Ju Choi
TOTiong Kiam Ong
Tiong Kiam Ong
HLHoungbang Liew
Houngbang Liew
MCMyeong-Chan Cho
Myeong-Chan Cho
Korean Circulation Journal 대한심장학회지 순환기 Yingchoncharoen T, et al. Korean Circ J. 2021 Aug;51(8):681-693. https://doi.org/10.4070/kcj.2021.0029

1 January 2026 in Hypertension
Verified
Journal Article
Open access
KKKazuomi Kario
Kazuomi Kario
AAAmir Aziz Alkatiri
Amir Aziz Alkatiri
JAJiro Aoki
Jiro Aoki
WAWan Azman Wan Ahmad
Wan Azman Wan Ahmad
YCYook-Chin Chia
Yook-Chin Chia
TWTzung-Dau Wang Wang
Tzung-Dau Wang Wang
The second Asia Renal Denervation Consortium consensus conference shared information and developed updated recommendations for renal denervation (RDN). Current evidence confirms that RDN significantly reduces blood pressure across all metrics (office, home, and ambulatory) throughout 24 hours. Modern RDN approaches target the distal main renal artery and branches where nerves more closely approximate the vessel wall. Understanding renal artery anatomy is crucial; the main renal artery typically divides into anterior and posterior divisions as first-order branches, which further subdivide into second-order segmental arterial branches. Renal artery electrical stimulation shows promise as a procedural end point, with blood pressure response attenuation after successful RDN suggesting adequate denervation, though the optimal procedural end point remains to be established. The indication for RDN is resistant or uncontrolled hypertension, with high office, home, or 24-hour ambulatory blood pressure readings despite appropriate lifestyle modification and antihypertensive drug therapy. Preprocedure assessment includes comprehensive screening for secondary causes and detailed renal artery imaging. Checklists for preprocedure and postprocedure assessment are provided. Nocturnal hypertension and morning hypertension, which are common in Asia, are more closely associated with cardiovascular risk than daytime hypertension and are more difficult to control with current guideline-driven medication. Based on these Asian characteristics and RDN’s long-term durability, RDN should be considered an effective option for facilitating optimal 24-hour blood pressure control. Future research through real-world data collection will help determine ethnic differences in RDN response between Asians and Westerners and identify optimal candidates. In addition, studies are needed to evaluate RDN’s ability to prevent organ damage and cardiovascular events.

1 July 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JCJaya Chandrasekhar
Jaya Chandrasekhar
SSSamantha Sartori
Samantha Sartori
MAMelissa B. Aquino
Melissa B. Aquino
UBUsman Baber
Usman Baber
PHPetr Hájek
Petr Hájek
RMRoxana Mehran
Roxana Mehran

24 March 2026 in Journal of Asian Pacific Society of Cardiology
Verified
Journal Article
Open access
HLHwei Sung Ling
Hwei Sung Ling
BCBui Khiong Chung
Bui Khiong Chung
AFAlan Yean Yip Fong
Alan Yean Yip Fong
TOTiong Kiam Ong
Tiong Kiam Ong
YCYee Ling Cham
Yee Ling Cham
Background: Heart failure (HF) is a leading cause of morbidity and mortality globally, with Southeast Asia seeing a rising disease burden. Multidisciplinary HF clinics (MDHFCs) offer a structured approach to optimise guideline-directed medical therapy, yet their effectiveness in middle-income countries remains underreported. Methods: This retrospective observational study aims to evaluate clinical outcomes and treatment optimisation in patients with HF with reduced ejection fraction enrolled in a MDHFC in Sarawak, Malaysia. The study included 172 patients enrolled from 2016 to 2020 at Sarawak Heart Centre. Patients were followed for 12 months. Primary outcome was a composite of cardiovascular mortality, HF hospitalisation or ambulatory worsening HF visits. Secondary outcomes included changes in New York Heart Association class, echocardiographic parameters and prescriptions for HF therapies. Results: Over 12 months, no cardiovascular deaths were recorded. HF hospitalisation and ambulatory worsening HF occurred in 9.5% and 11.3% of patients, respectively. Significant improvements in left ventricular ejection fraction (24.5–39.1%, p<0.001) and New York Heart Association class were observed. Uptake of angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitor, β-blockers, mineralocorticoid receptor antagonists and sodium–glucose cotransporter-2 inhibitors increased markedly, with β-blockers prescribed in 91.5% of patients. Triple therapy use rose from 49.4% to 59.1%; quadruple therapy uptake remained low (1.8%). Conclusion: The MDHFC model improved clinical outcomes, functional status and medication optimisation despite resource limitations. These findings support the feasibility and effectiveness of MDHFCs in similar healthcare settings and highlight their potential scalability in middle-income countries.

26 April 2022 in Journal of Asian Pacific Society of Cardiology
Verified
Journal Article
Open access
PDF file
STShirley Siang Ning Tan
Shirley Siang Ning Tan
KKKeng Tat Koh
Keng Tat Koh
AFAlan Yean Yip Fong
Alan Yean Yip Fong
Mohamad Adam BujangMohamad Adam Bujang
Mohamad Adam Bujang
LTLee Len Tiong
Lee Len Tiong
TOTiong Kiam Ong
Tiong Kiam Ong
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) provides prognostic information regarding the risk of death, acute heart failure and the development of AF in patients with acute coronary syndrome. While there are established cut-off values for the association between clinical risk assessment scores and in-hospital mortality, there is no clear cut-off value for NT-proBNP to guide risk stratification in patients with acute MI (AMI). Our study sought to evaluate the cut-off values of NT-proBNP in all-cause mortality post AMI and to compare with other available risk assessment scores. Methods: We conducted a multi-centre, prospective, observational study involving 411 patients admitted for AMI. Plasma NT-proBNP was assessed within 24 hours of admission. Results: One-year all-cause mortality occurred in 31 (7.6%) of 411 patients. NT-proBNP ≥404 pg/ml had an area under the curve of 0.66 (95% CI [0.54–0.77]; p=0.004) to predict all-cause mortality at 1 year (sensitivity: 80.6%; specificity: 36.9%; positive predictive value: 9.47%; negative predictive value: 95.89%). Using the Youden index, an NT-proBNP level ≥1,995 pg/ml was an independent predictor of all-cause mortality at 1 year (adjusted HR 2.6; 95% CI [1.3–5.5]; p=0.010), regardless of cardiovascular disease risk factors or revascularisation status. There were no significant differences among the predictive values of NT-proBNP, Thrombolysis in MI risk score, Global Registry of Acute Coronary Events risk score and left ventricular ejection fraction in predicting all-cause mortality at 1 year (p>0.05). Conclusion: NT-proBNP level ≥1,995 pg/ml measured within 24 hours of admission for AMI was associated with higher all-cause mortality at 1 year. Randomised controlled trials are needed to further validate the usefulness of NT-proBNP for risk stratification in patients with AMI.